Bernard Escudier

Shares of Exelixis, Inc. (NASDAQ: EXEL) surged higher by more than 7 percent at $5.90 early Tuesday morning after the company announced positive results from its METEOR Phase 3 pivotal trial of cabozantinib. Exelixis' phase 3 pivotal trial involved 658 patients with renal cell carcinoma....